Glibenclamide Inhibits Cell Growth by Inducing G0/G1 Arrest in the Human Breast Cancer Cell Line MDA-MB-231

The study demonstrated that glibenclamide (Gli) inhibited the proliferation of the MDA-MB-231 breast cancer cell line by inducing G0/G1 cell cycle arrest. This effect was associated with the up-regulation of p27 and a decrease in cyclin E expression, suggesting that Gli's action might be mediated through ATP-sensitive potassium channels (KATP channels). Gli's antiproliferative effect was enhanced when combined with doxorubicin, indicating its potential as an adjuvant in breast cancer treatment. The study highlighted Gli's cytostatic effect, as no differentiation or apoptosis was detected, and suggested its potential use as a therapeutic agent for non-hormone dependent breast cancer.